title: [Significance of HER2 testing in breast cancer].
authors.forename: Yun-bi
authors.initials: YB
authors.lastname: Ni
authors.forename: Wen-juan
authors.initials: WJ
authors.lastname: Yang
authors.forename: Hong
authors.initials: H
authors.lastname: Bu
authors.forename: Hong
authors.initials: H
authors.lastname: Zheng
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000378:metabolism*; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D000077289:Letrozole; D009570:Nitriles / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D015996:Survival Rate; D013629:Tamoxifen / Q000627:therapeutic use; D000068878:Trastuzumab; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077289:Letrozole; D009570:Nitriles; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen; D000068878:Trastuzumab; D014230:Triazoles